Phase 1 and Other Cancers

The following list provides a brief description of Phase 1 and other cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.

 

IN10018-004-01

Registered Title A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma
Purpose  This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and
antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in
subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

BGB-A317-A445-101

Registered Title  Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Purpose  This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and
antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in
subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.
Lay Summary  N/A
WA Trial Sites 

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

Maxinovel-10181-001

Registered Title A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Purpose  This is a multi-center, first-in-human, non-randomized, open-label, single-arm,
dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in
patients with advanced solid tumor.
Lay Summary  N/A
WA Trial Sites 

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

BGB-900-105

Registered Title Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Purpose  BGB-A1217 is a humanized, IgG1 monoclonal antibody against TIGIT. Tislelizumab is a
humanized, IgG4-variant monoclonal antibody against PD-1. This study tests the safety and
anti-tumor effect of BGB-A1217 in combination with tislelizumab in patients with advanced
solid tumors.
Lay Summary N.A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

Selpercatinib EAP

Registered Title Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Purpose  Expanded access for patients with cancer with RET activation who are ineligible for an
ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

MK-7339-007 / KEYLYNK-007

Registered Title  A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Purpose  The purpose of this study is to assess the efficacy and safety of treatment with olaparib
(MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated,
advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm)
and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

2K-MC-JZKA

Registered Title  A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation
Purpose  The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

THOR-707-101

Registered Title  An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination With a Checkpoint Inhibitor in Adult Subjects With Advanced or Metastatic Solid Tumors
Purpose  This is an open-label, First-in-Human, dose escalation and dose expansion study of THOR-707
(Monotherapy and Combination Therapy) in adult subjects with advanced or metastatic solid
tumors.
Lay Summary  N/A
WA Trial Sites  
St John of God Subiaco Ph. (08) 6465 9204
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

204691

Registered Title  A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Purpose  GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody
intended for the treatment of cancers of different histology. This is a first-time-in-human
(FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and
preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the
aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and
in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two
primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as
dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination
therapy with Part 2A pembrolizumab or GSK3174998 combination dose escalation phase and Part
2B expansion phase with pembrolizumab. Part 2A GSK3359609 combinations with chemotherapy will
only consist of safety run-in cohorts. Each part and phase of the study includes a screening
period, a treatment period, and a follow-up period. The primary objective of the study is to
determine the safety, tolerability, maximum tolerated dose or the maximum administered dose
of GSK3359609 alone or in combination.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

FLX475-02

Registered Title  Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Purpose This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort
expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as
monotherapy and in combination with pembrolizumab.

The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort
expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential
cohorts treated with successively higher doses of FLX475 as monotherapy or in combination
with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of
parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.

Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

BGB-900-102

Registered Title Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Purpose  BGB-A425 is a humanized, IgG1-variant monoclonal antibody against TIM-3. Tislelizumab is a
humanized, IgG4-variant monoclonal antibody against PD-1. This study tests the safety and
anti-tumor effect of BGB-A425 in combination with tislelizumab in patients with advanced
solid tumors.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

BGB-900-103

Registered Title A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Purpose  This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with histologically or cytologically confirmed locally advanced or metastatic tumors including non- squamous NSCLC, RCC, or OC.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

MK-7339-002 / LYNK-002

Registered Title A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Purpose This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in
participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1)
have progressed or been intolerant to standard of care therapy; and 2) are positive for
homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Lay Summary  N/A
WA Trial Sites

  
Linear Clinical Research 0437 873 044

LInks  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

B9991025 / Javelin PARP Medley

Registered Title

A Phase 1B/2 study to evaluate safety and anti-tumour activity of Avelumab in combination with the Poly (Adenosine diphosphate [ADP] - ribose) polymerase (parp) inhibitor talazoparib in patients with locally advances or metastatic solid tumours

Purpose  Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).
Lay Summary  N/A
WA Trial Sites  Cancer Centre Clinical Trials Unit
Phone 08 615 26530
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

BGB-283/PD-0325901-AU-001

Registered Title A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors
Purpose  This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 combination in
patients with tumors.
Lay Summary  N/A
WA Trial Sites

 

Linear Clinical Research 0437 873 044

Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

AM-ATX101-01

Registered Title A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours
Purpose This is a Phase I, open-label, single arm, safety and tolerability study which will evaluate escalating dose cohorts of ATX-101 to determine the maximum tolerated dose in subjects with advanced solid tumours.

Who is it for?
You may be eligible to join this study if you are aged 18 years or above, have advanced solid tumours for which conventional anti-tumour treatment has been exhausted or has been refused

Study details
The study is designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) for ATX-101. Dose escalation will be determined based on recommendations from a Safety Review Committee and is expected to occur over a total of 6 cohorts.

Potential study subjects who provide voluntary written informed consent will undergo screening evaluations to determine eligibility within 28 days prior to enrolment and the start of treatment (Day 1). Eligible subjects will be admitted to the study centre on Day 1 for the first dose of study drug to be administered by IV infusion. Prior to each treatment infusion the subject will receive mandated pre-medication. Treatment will be administered weekly in cycles of 21-day duration, with a single IV infusion of ATX-101 on Day 1, 8 and 15. Dosing of subjects will occur weekly for up to two cycles (i.e. 2 x 21 days = 6 weeks), or until criteria for early termination is met.

After completion of the end of study visit, subjects without documented progressive disease may be approved to continue weekly treatment under a separate long term follow up protocol (AM ATX101-02). Under Protocol AM ATX-101-02, subjects are to be monitored by tumour imaging every 3 months (± 14 days) until documentation of progressive disease.

Lay Summary  N/A
WA Trial Sites

  

Linear Clinical Research 0437 873 044

Links  Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

APOLLO

Registered Title A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
Purpose  This study will enroll subjects with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A subjects will receive BGB-290; in Arm B subjects will receive placebo. The purpose of this study is to show that BGB-290 (versus placebo) will improve progression-free survival (PFS) in subjects with advanced or inoperable gastric cancer.
Lay Summary  N/A
WA Trial Sites  
Cancer Centre Clinical Trials Unit
Phone 08 615 26530
Links US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

ARCS Study

Registered Title Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
 Purpose  The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
 Lay Summary N/A 
 WA Trial Sites

 

SCGH - Medical Oncology (08) 6383 3000

 LInks  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

C-550-01

Registered Title   An Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Patients with Metastatic or Locally Advanced Solid Tumours
Purpose   N/A
Lay Summary    N/A
WA Trial Sites    
 Linear Clinical Research 0437 873 044
Links   US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

Checkmate 020        CA224-020

Registered Title A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Purpose The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery.
Lay Summary An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
WA Trial Sites

   
Linear Clinical Research 0437 873 044

Links US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

P3BEP Germ Cell Tumour Study

Registered Title

Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours.

Purpose

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

Lay Summary

Who is it for?   You may be eligible to join this study if you are a male aged 16 years to 45 years old and you have been diagnosed with metastatic germ cell tumour/s in the testes, retro-peritoneum or mediastinum.

Study details:    Participants in this study will be randomly (by chance) allocated to one of two groups. Participants in one group will receive the current gold standard treatment for germ cell tumours, which is a chemotherapy combination called BEP (bleomycin, etoposide and cisplatin) administered on a 3 weekly cycle. BEP is given with a drug called pegfilgrastim which encourages white blood cell production and prevents blood cell complications of chemotherapy. Participants in the other group will receive the same dose of BEP but on a 2 weekly schedule. This is called 'accelerated BEP'.

WA Trial Sites

Fiona Stanley Hospital Logo

Cancer Centre Clinical Trials Unit
Phone 08 615 26530 

Links

Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

M15-891

Registered Title   A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody, as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors
Purpose  A Study of ABBV-181 in Participants With Advanced Solid Tumors
Lay Summary This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181.
WA Trial Sites     
Linear Clinical Research 0437 873 044
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

BGB COMBO

Registered Title
 A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
 Purpose  The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
 Lay Summary
 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

CA017-003

Registered Title
 A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
 Purpose The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
 Lay Summary
 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

AK104-101

Registered Title
 A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
 Purpose This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK104 as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK104 as a single agent, and a dose expansion phase (Phase 1b) which will characterize treatment of AK104 as a single agent at the MTD or RP2D.

 Lay Summary

 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

INCAGN1876-102

Registered Title
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
 
 Purpose  The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
 Lay Summary
 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

CA020-002

Registered Title
Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumours
 Purpose The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself and in combination with Nivolumab in solid cancers that are advanced or have spread.
 Lay Summary
 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

I8S-MC-JUAB

Registered Title
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Purpose The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
Lay Summary
 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

GSK204691

 Registered Title

A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumours

 Purpose  GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab combination dose escalation phase and Part 2B cohort expansion phase. Part 2A GSK3359609 combinations with chemotherapy will only consist of safety run-in cohorts. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
 Lay Summary
 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

EMR200647

 Registered Title
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
 Purpose  The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals. Based on this information, it is hoped to find out which dose could be best for the treatment of patients. There are two parts of this research study: a dose-escalation part and an expansion part. Dose escalation means that the first people taking part in the study will receive low doses of the study drug, and as more people take part, the additional participants will receive a higher dose. This is done to find the safest dose for the study drug. Expansion means that after the dose-escalation part of the study has looked at the safety and effectiveness of different doses, many more people will be invited to take part in the study and will receive the study drug at the safest dose. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.
 Lay Summary
 N/A
 WA Trial Sites

Linear Clinical Research 0437 873 044

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

BGB-290-AU-002

Registered Title
 A Phase IA/IB, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors
 Purpose  This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-290 in patients with solid tumors.
 Lay Summary
 N/A
 WA Trial Sites

 Linear Clinical Research 0437 873 044

 Links US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

Bayer Arcs Multi

Registered Title Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
Purpose The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.

The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas.

Lay Summary  N/A
WA Trial Sites

St John of God - Subiaco (08) 6465 9204

Links US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

Nivo Pass

Registered Title


Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

 

Purpose  This is an observational, multicenter study in patients treated with nivolumab for the approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the United States (US). Targeted countries in the EU for study participation include Austria, Belgium, France, Germany, Italy, Spain, and the United Kingdom (UK). Study objectives are to assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab in routine oncology care facilities.
Lay Summary  N/A
WA Trial Sites   ST John Of God Subiaco (08) 6465 9204
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

UNITY-NHL-trial

Registered Title  A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma
Purpose This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in combination with another study drug called ublituximab with or without bendamustine and TGR-1202 alone as a possible treatment for Non-Hodgkin's Lymphoma (NHL) that has come back or that has not responded to standard treatment.
Lay Summary Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
WA Trial Sites   Hollywood Private Hospital (08) 9346 6637
 Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

[Return to List of Clinical Trials]